Kornimate/medical-research-clean huggingface dataset:
validity and reliability of the 2-minute step test in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: the objective of this study was twofold: first, to assess the validity and reliability of the 2 minute step test (2mst) in patients with fibromyalgia; and second, to explore its relationship with objective assessment methods, specifically the 2 minute walk test (2mwt) and the 6 minute walk test (6mwt). additionally, the study aimed to investigate the correlation between the 2mst and quality of life as well as chronic fatigue levels using the fibromyalgia impact questionnaire (fiq) and the fatigue severity scale (fss).

this cross-sectional study will include 55 female patients aged 18-65 who will be diagnosed with fibromyalgia according to the american college of rheumatology 2010 diagnostic criteria. demographic characteristics of the patients will be documented. the extent of impact on patients' quality of life will be evaluated using the fibromyalgia impact questionnaire (fiq), while the severity of chronic fatigue will be measured using the fatigue severity scale (fss). the intensity of chronic pain experienced by patients will be expressed using the visual analogue scale (vas). all patients will undergo an initial assessment using the 2-minute step test (2mst), 2-minute walk test (2mwt), and 6-minute walk test (6mwt). to assess test-retest reliability, the 2mst will be repeated with a 7-day interval between assessments.

Eligibility criteria:
inclusion criteria: * having been diagnosed with fibromyalgia according to the american college of rheumatology 2010 diagnostic criteria * female patients aged 18-65 * the absence of any pathological condition that would hinder walking exclusion criteria: * uncontrolled hypertension * decompensated heart failure * presence of systemic diseases affecting lower extremity functions * presence of degenerative diseases affecting lower extremity functions * peripheral artery disease causing vascular claudication * psychiatric illness * neuromuscular disease * pregnancy * cognitive impairment

Keywords: fibromyalgia exercise test physical fitness
study of capsule endoscopy to determine the accuracy for detection of esophageal varices

Conditions: Esophageal Varices

Summary: esophageal capsule endoscopy is sedation-less alternative to upper endoscopy for evaluating esophageal lesions and potentially other upper gastrointestinal lesions. the purpose of this study was to determine whether esophageal capsule endoscopy is convenient and accurate as upper endoscopy for detection of esophageal varices and related lesions.


Eligibility criteria:
inclusion criteria: * age at least 18 years and less than 86 years at the time of consent. * clinically evident or biopsy proven cirrhosis. * no previous documented ugi bleeding due to peptic ulcers, varices, portal hypertensive gastropathy, angiomas, or watermelon stomach. * no previous endoscopic, radiological or surgical treatment for variceal bleeding or ascites. * probable life expectancy of at least 24 months without liver transplantation, as judged by the hepatologist and endoscopist-investigators, and have a model for end-stage liver disease (meld) score ≤ 29. * signed a written informed consent. exclusion criteria: * prior variceal bleeding- esophageal, gastric, or other site. * prior endoscopic (e.g. sclerotherapy, ligation, or combination therapy), radiological (e.g. transjugular intrahepatic portosystemic shunt-tips) or surgical (e.g. portocaval or splenorenal shunt) treatment of esophagogastric varices or ascites. * patient who was uncooperative or unable to give written consent. * severe co-morbid illness, e.g. end stage chronic renal disease (e.g. dialysis dependence, creatinine greater than 2 times normal) or respiratory failure (e.g. ventilator dependent, oxygen dependent, unstable asthma or chronic obstructive pulmonary disease- e.g. 2 or more hospitalizations for exacerbation in 1 year, asthma or obstructive pulmonary disease which required daily bronchodilators and/or oral/inhaled steroids), tense ascites requiring repeated therapeutic paracenteses, severe hepatic encephalopathy, peritonitis, or sepsis. * active cancer with less than a 24 month expected survival and/or cancer on active treatment with chemotherapy and/or radiation therapy. * esophageal motility disorder, esophageal stricture or esophageal diverticulum, causing dysphagia or requiring dilatation. * gi obstruction or partial obstruction (by history or imaging), symptomatic gi stricture or pseudo-obstruction which may prevent passage of the capsule. * patients with potentially reversible portal hypertension such as alcoholic hepatitis, acute viral hepatitis, untreated autoimmune hepatitis, or chronic hepatitis b or c on viral therapy.

Keywords: esophageal capsule endoscopy, screening
the long-lasting effects of repetitive neck muscle vibrations on postural disturbances in standing position in chronic stroke patients

Conditions: Hemiplegia; Stroke

Summary: one of the causes of disability in patients suffering from a stroke is postural imbalance. sensory stimulation improves the postural symmetry of the subject transitorily and they are thought to have an effect on the spatial frame of reference through a sensory recalibration. studies have shown that sensory stimulation by vibration of neck muscles have an immediate effect on static balance and when walking. the objective of this preliminary study is to test the long-lasting effects of repetitive neck muscle vibrations on postural disturbances in standing position and on spatial frame reference in chronic patients.

the hypothesis of this study is that the proprioceptive repeated stimulation by vibration of neck muscles in the long term improved postural asymmetry in connection with the egocentric representation of body disorders. the effect of vibration simultaneously on improving postural asymmetry and on improving markers of the perception of the body in space (lba, ssa, subjective visual vertical (svv), rod and frame) will be assessed.

Eligibility criteria:
inclusion criteria: * adult (age ≥ 18 years) under 80 years, * right or left unilateral supratentorial ischemic or hemorrhagic lesion * the first symptomatic episode * stroke * older than 12 months * with or without hemianopsia * with or without visuospatial hemineglect * standing balance ≥ 30 sec unaided * percentage of weight bearing asymmetry on the hemiplegic lower limb (on a force platform) * written informed consent of the patient or a member of his entourage (in the case of patients with motor difficulties) exclusion criteria: * orthopaedic, rheumatologic, neurologic, vestibular or visual disorders affecting the distribution of the centre of pressure while standing on the force platform * visual disorder that does not allow assessment of the spatial frame of reference test * difficulty with understanding protocol procedures
evaluate the efficacy and safety of abt-126 in subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate alzheimer's disease.

this is a phase 2 study designed to evaluate the efficacy and safety of abt-126 in approximately 410 adults with mild to moderate alzheimer's disease. subjects will be randomized to one of 5 treatment groups (abt-126, donepezil or placebo) for a 24-week treatment period.

Eligibility criteria:
inclusion criteria: * the subject and caregiver must voluntarily sign and date an informed consent. if the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject. * the subject is a male or female between the ages of 55 and 90 years, inclusive, at screening visit 1. * the subject meets the national institute of neurological and communicative disorders and stroke/alzheimer's disease and related disorders association (nincds/adrda) criteria for probable alzheimer's disease. * the subject has a mini-mental status examination (mmse) total score of 10 to 24, inclusive, at screening visit 1. * the subject has a cornell scale for depression in dementia (csdd) score ≤ 10 at screening visit 1. * the subject has a modified hachinski ischemic scale (mhis) score of ≤ 4 at screening visit 1. * with the exception of a diagnosis of mild to moderate ad and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ecg). * the subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study. exclusion criteria: * the subject is currently taking or has taken a medication for the treatment of alzheimer's disease or dementia within 60 days prior to screening visit 1, or is participating in cognitive therapy for the treatment of alzheimer's disease or dementia. * the subject has clinically significant abnormal laboratory values at screening visit 1 as determined by the investigator. * the subject has a history of any significant neurologic disease other than alzheimer's disease including parkinson's disease, multi-infarct or vascular dementia, huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities. * in the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness. * the subject has a known hypersensitivity or intolerance to donepezil that lead to discontinuation or a known reported history of donepezil treatment failure.
evaluation of the api-vigie monitoring system: program to reduce emergency visits for severe paroxysmal alcoholism

Conditions: Intoxication;Alcohol;Acute; Emergencies

Summary: the study was designed to evaluate the apivigie program use at ch d'arras. the objective of this program is to reduce repeated visits by the same patient to the emergency room for alcoholism severe paroxysmal

in france, between 10% and 30% of emergency room admissions are linked to problematic alcohol consumption. this considerable weight of alcohol-related problems in the current problematic of emergencies is largely unknown and can lead to blockages in emergencies. for acute intoxication requiring emergency care, 80% of admissions concern people dependent on alcohol. here again, this crucial clinical notion is largely ignored: when a patient in a state of intoxication arrives in the emergency room, this should not be considered as a banal and one-off event, it is necessary to put in place a care, if necessary, of addiction. supported by a call for projects from the hauts-de-france regional health agency, the addictions service of the arras hospital is setting up a monitoring system called apivigie. apivigie program is offered to patients who present to the emergency room for a diagnosis of api after an evaluation by the liaison team of the addiction service. if the patient agrees to be part of the program, he will receive a resource card with the apivigie phone number to contact if necessary. the link will be maintained with the addictology care, support and prevention center (csapa) for a period of 6 months, by telephone consultations, or by video-consultations or face-to-face consultations.

Eligibility criteria:
inclusion criteria: * patient 18 years or older; * participant at api-vigie program. exclusion criteria: * patient's opposition to participating in the research; * persons under legal protection (under tutorship or curatorship); * person deprived of liberty; * pregnant or breastfeeding women.

Keywords: intoxication;alcohol;acute addiction, alcohol binge drinking young adult
relationship between hip abductor strength and ankle stability

Conditions: Fatigue

Summary: ankle sprains are one of the most common injuries in sports. the analysis of risk factors is a priority in order to guide rehabilitation and prevention programs. among risk factors identified in the literature, weakness of the hip abductor muscles represent a factor favoring recurrent ankle sprains. however, only few studies have investigate the link between the strength of the hip abductor muscles and the deficits in stabilization of the ankle joint. furthermore, these few studies analysed landing task or undisturbed balance task. it would be interesting to further understand the impact and role of hip abductor muscles on ankle stability during specific ankle-destabilizing task. the main objective of this study is to establish a link between the strength of the hip abductor muscles and the dynamic postural control performance measured by the modified star excursion balance test (sebtm). secondly, it will be necessary to study the kinematic and neuromuscular control characteristics of the ankle during 4 functional tests: * sebtm * static unipodal balance * weight-bearing inversion test * weight-bearing eversion test these tests will be realized with an ankle destabilizing device. the device is a sandal equipped of an articulator under the rear foot which allow movements in inversion and eversion. furthermore, tests are realized two times, before and immediatly after a fatiguing exercise. the fatiguing exercise consists to implemented local fatigue on hip abductor muscles by repeating abductions.


Eligibility criteria:
inclusion criteria: * males and females between 18 and 35 years old * subject's non-opposition to participate in the study * practicing regular physical activity (\> 2 hours per week) * no contraindication to carrying out the protocol * affiliation to a french social security scheme or beneficiary of such a scheme exclusion criteria: * males or females under 18 or over 35 years * history of lower limb injuries in the 6 months preceding the protocol * diagnosis of chronic ankle instability * subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator * subject's opposition to participating in the study * subject without health insurance * pregnant woman

Keywords: balance ankle destabilization prevention hip fatigue
vaccine therapy for multiple myeloma utilizing idiotype-pulsed allogeneic dendritic cells

Conditions: Multiple Myeloma

Summary: patients with multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.

to evaluate feasibility and safety of vaccination with allogeneic idiotype-pulsed dendritic cells following mixed chimeric allogeneic transplantation for multiple myeloma.

Eligibility criteria:
inclusion criteria:1. for specimen collection and idiotype protein development: * must be secretory myeloma with at least .5g/dl serum igg protein * clinically stage 2 or 3 multiple myeloma * karnofsky performance status of 70 or greater 2. for vaccination: * eligible patients must have completed tandem autologous and nonmyeloablative allogeneic transplant for multiple myeloma at stanford university medical center with stable disease or complete response to prevaccine therapy * karnofsky performance status of 70 or greater. * alt and ast must be \<2x upper limit of normal. total bilirubin \< 1.5x upper limit of normal. * serum creatinine \<1.5x upper limit of normal. * hemoglobin \>9g/dl * patients must be hiv negative. * patients must provide signed, informed consent donor inclusion criteria (allo donor is the same donor used for non-myeloablative transplant) * age \>17 years * hiv negative * must provide signed, informed consent exclusion criteria:1. for specimen collection and idiotype protein development: * patients with non-secretory myeloma * severe psychological or medical illness * pregnant or lactating women * subjects with \> grade i toxicity by nci-ctc v 3.0 * subjects with prognosis \< 6 months 2. for vaccination: * \< 75 mg of idiotype protein purified from the patients serum * \< 25 million allogeneic idiotype-pulsed dendritic cells produced for vaccination * evidence of grade ii-iv acute gvhd (defined in section 5e) * patients with evidence of myeloma disease progression as (defined below) * severe psychological or medical illness or concomitant medications which may interfere with the study as determined by the clinical investigator * patients on any other investigational agents * pregnant or lactating women * patients on any therapy for multiple myeloma or any chemotherapy drug, or immunomodulatory agent for treatment of multiple myeloma (e.g. thalidomide) * any patient on more than two of the following immunosuppressive agents or at a dose greater than that indicated for a single immunosuppressive agent: 1. mycophenolate mofetil (mmf)- no greater than 1000mg twice a day 2. prednisone- no greater than .5mg/kg/day 3. cyclosporine- no greater than 300mg/day 4. tacrolimus (fk506)- no greater than 4mg/day
high definition single cell analysis in colorectal cancer

Conditions: Metastatic Carcinoma in the Liver; Stage IV Colorectal Cancer

Summary: this research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver. high definition single cell analysis allows doctors to study the properties of cancer cells that are sometimes found in the blood of patients and to determine how the genes and proteins in them may change over time. studying samples from patients with colorectal cancer in the laboratory may help doctors learn more about how cancer spreads, as well as how to predict the disease outcomes in patients with cancer.

primary objectives: i. to determine the level of correlation between solid tumor touch preparations and liquid biopsies (circulating tumor cells \[ctcs\]) from patients with surgically resected colorectal cancer (crc) metastases to the liver using single-cell high-content analysis, including gene copy number variation (cnv) and to establish one or more bio-signatures that represent the liquid and solid biopsy correlation for each patient and for the patient population. secondary objectives: i. to demonstrate the technical validity and reproducibility of the bio-signatures by comparing the two pre-resection liquid biopsy samples drawn one week prior to and on the day of surgery. tertiary objectives: i. compare biosignatures between pre-surgical and post-surgical blood samples. ii. compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue (if available), and pre-surgical blood samples. iii. compare biosignatures between blood samples prior to resection with those obtained after resection and at the time of recurrence. outline: patients undergo blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. patients also undergo tissue collection during the surgery. blood and tissue samples are processed for high definition single cell analysis including whole-genome cnv profiles, protein expression, and cell morphology. after completion of study, patients are followed up for up to 2 years.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * metastatic colorectal adenocarcinoma to the liver (hepatic mcrc) * synchronous or metachronous * solitary or multifocal * concurrent abdominal lymph node metastasis is allowable * hepatic mcrc deemed surgically resectable by the study team with plans to undergo surgery * has not received any systemic chemotherapy for at least 21 days prior to scheduled hepatic resection exclusion criteria: * non-adenocarcinoma metastatic colorectal cancer (e.g. neuroendocrine carcinoma); mucinous component is permitted * metastatic crc that involves organ(s)/tissue(s) other than abdominal lymph nodes and/or liver * has received any systemic chemotherapy within 21 days prior to scheduled hepatic resection
psychoeducation for hepatitis and alcohol behaviors

Conditions: Hepatitis C; Substance Abuse

Summary: the proposed project will apply a unique, effective family-responsive psychoeducation program, psychoeducation responsive to families (perf), for hepatitis c virus (hcv) treatment. the goal is to demonstrate that the intervention will enlarge the eligibility of some patients for hcv treatment and help sustain others through it.

this study aims to evaluate the utility of a psychosocial intervention (psychoeducation responsive to families; perf), applied to help patients prepare for and sustain hcv treatment in the treatment setting. through careful psychiatric diagnosis and multiple longitudinal assessments, this study will also shed further light on the course of comorbid alcohol use, drug use, and other psychiatric syndromes and their interrelationships. the proposed study combines an innovative psychoeducation program with traditional hcv patient care and education. the goal of this work is to improve treatment adherence, allowing individual drug regimens to achieve their optimal effectiveness and reach a wider patient population. support and sustenance of patients from a psychosocial perspective while they are in treatment should also help deliver more patients to sustained suppression of hcv as well as help presently untreated patients and populations become candidates for this therapy-ultimately reducing the disease burden of increasing numbers of patients needing liver transplantation or facing imminent death.

Eligibility criteria:
inclusion criteria: 1. individuals who are seropositive for hcv as determined by elisa test and confirmed by direct measure of viral load as part of their clinical care 2. lack progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy) 3. age at least 18 years 4. identified family member(s)/significant other(s) also willing to participate in the psychoeducation groups, and 5. ability to provide informed consent for research participation. "family" will be defined to include biological relatives, as well as any non-biological individual or significant other considered "family" by either the ill member or his/her immediate family. exclusion criteria: 1. inability to provide informed consent such as irreversible cognitive impairment precluding participation 2. progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy), and 3. age \<18 years.

Keywords: hepatitis c substance abuse psychoeducation psychiatric functioning physical functioning quality of life niaaa alcohol